{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-010515","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.441096+00:00","generated_at":"2026-05-16T10:56:41.751327+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"SAB Biotherapeutics posts updated corporate presentation; no financial or operational details disclosed","bullets":["Filed under Item 7.01 Regulation FD; presentation posted on company website.","No specific financial metrics, pipeline updates, or guidance changes provided in the filing.","Presentation titled 'Modifying Disease, Delaying Progression, Transforming Treatment' suggests therapeutic focus."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-010515","json":"https://secwatch.observer/filing/0001193125-26-010515.json","markdown":"https://secwatch.observer/filing/0001193125-26-010515.md","text":"https://secwatch.observer/filing/0001193125-26-010515.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526010515/0001193125-26-010515-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526010515/sabs-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:56:41.751327+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}